There are other ongoing clinical trials of immune checkpoint inhibitors nivolumab and durvalumab in patients with IDH-mutant gliomas (NCT03991832, NCT03557359, NCT03718767, NCT03925246) (Table 2 and Table 3). This evidence concerns the gene IDH1 and central nervous system cancer.